Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)
Status:
Completed
Trial end date:
2019-03-21
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy of lenalidomide associated with CHOP as measured by
complete response rate at the end of treatment. Approximately 80 patients aged between 60 and
80 years will be included, to have 70 evaluable patients. The treatment consists of two
phases of four 3-weeks cycles: induction phase and consolidation phase, for a total treatment
duration of 24 weeks. Each cycle will be broken down as follows: chemotherapy will be
administered in the hospital on day 1, prednisone is continued for 5 days and lenalidomide is
taken for 14 days. Patients will be followed for at least 18 months after inclusion of the
last patient.